TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

Mutations in the tumor protein 53 (TP53) gene predict a poor prognosis in patients with acute myeloid leukemia (AML).

[1]  J. Radich,et al.  FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. , 2001, Blood.

[2]  L. Möllgård,et al.  Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia , 2008, Leukemia & lymphoma.

[3]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[4]  V. Rotter,et al.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. , 2000, Cancer research.

[5]  T. Naoe,et al.  Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia , 2000, European journal of haematology.

[6]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[7]  T. Soussi,et al.  p53 mutation heterogeneity in cancer. , 2005, Biochemical and biophysical research communications.

[8]  V. Rotter,et al.  Mutant p53 protein expression interferes with p53-independent apoptotic pathways , 1998, Oncogene.

[9]  H. Einsele,et al.  TP53 mutation in patients with high‐risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation , 2016, British journal of haematology.

[10]  Kerby Shedden,et al.  Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. , 2010, Blood.

[11]  Sigrun M. Hjelle,et al.  Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia , 2012, Oncogene.

[12]  J. Downing,et al.  Mouse models of human AML accurately predict chemotherapy response. , 2009, Genes & development.

[13]  Michael B. Mann,et al.  Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice , 2015, Oncotarget.

[14]  Yun Zhang,et al.  Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer , 2015, Front. Oncol..

[15]  D. Christiansen,et al.  Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Ehninger,et al.  The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia , 2009, Leukemia.

[17]  D. Christiansen,et al.  Genetics of therapy-related myelodysplasia and acute myeloid leukemia , 2008, Leukemia.

[18]  B. Ko,et al.  TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution , 2015, Blood Cancer Journal.

[19]  Torsten Haferlach,et al.  Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile , 2005, Genes, chromosomes & cancer.

[20]  Ken H. Young,et al.  Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. , 2015, Leukemia research.

[21]  M. Hollstein,et al.  p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM , 2007, Nature Cell Biology.

[22]  J. Aurelius,et al.  Immunotherapeutic strategies for relapse control in acute myeloid leukemia. , 2013, Blood reviews.

[23]  R. Hills,et al.  TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis , 2009, Leukemia.

[24]  L. Medeiros,et al.  Cytogenetic findings in blastoid mantle cell lymphoma. , 2003, Human pathology.

[25]  Magali Olivier,et al.  TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.

[26]  N. Emi,et al.  TP53 mutations in older adults with acute myeloid leukemia , 2016, International Journal of Hematology.

[27]  S. Fröhling,et al.  TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.